| pubmed-article:2962892 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0019169 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0011847 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:2962892 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:2962892 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:2962892 | pubmed:dateCreated | 1988-3-10 | lld:pubmed |
| pubmed-article:2962892 | pubmed:abstractText | Twenty patients with well controlled Type 1 (insulin-dependent) diabetes of at least 10 years duration and 47 control subjects were vaccinated against the hepatitis B virus using the Hevac B vaccine. The vaccine was administered into the deltoid region on three occasions at intervals of 1 month. Thereafter a fourth dose was given to subjects still negative for antibody to hepatitis B surface antigen (HbsAb). The median rise of HbsAb titres was 230 mIU/ml in normal subjects and 50 mIU/ml in diabetic patients (p less than 0.001). Eight patients (40%) failed to reach HbsAb titres above 30 mIU/ml, the level considered to give optimal protection against the infection, whereas only one normal control subject failed to reach this level. Five patients (25%) showed no response despite a fourth dose of the vaccine. There was an increased frequency of HLA-DR7 in low responders and a decreased (less than 1.5) helper/suppressor lymphocyte ratio. Diabetic patients are thus less likely to mount a protective antibody response following vaccination against hepatitis. Since hepatitis B surface antigen is reported to be considerably more common in diabetic patients than control subjects, infection with hepatitis B virus may have a greater risk of chronicity in diabetes. | lld:pubmed |
| pubmed-article:2962892 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2962892 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2962892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2962892 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2962892 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2962892 | pubmed:issn | 0012-186X | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:SutherlandJJ | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:GaleE AEA | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:PozzilliPP | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:GalliCC | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:BiasioLL | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:AndreaniDD | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:PezzellaMM | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:CorradiniS... | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:VisalliNN | lld:pubmed |
| pubmed-article:2962892 | pubmed:author | pubmed-author:ArduiniPP | lld:pubmed |
| pubmed-article:2962892 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2962892 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:2962892 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2962892 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2962892 | pubmed:pagination | 817-9 | lld:pubmed |
| pubmed-article:2962892 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:meshHeading | pubmed-meshheading:2962892-... | lld:pubmed |
| pubmed-article:2962892 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:2962892 | pubmed:articleTitle | Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. | lld:pubmed |
| pubmed-article:2962892 | pubmed:affiliation | Endocrinologia I, University of Rome La Sapienza, Italy. | lld:pubmed |
| pubmed-article:2962892 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2962892 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2962892 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2962892 | lld:pubmed |
